Literature DB >> 25685371

Adrenocorticotropic Hormone-Dependent Cushing's Syndrome: Use of an octreotide trial to distinguish between pituitary or ectopic sources.

Omayma T El-Shafie1, Nooralddin Al-Saffi1, Ahmed Al-Sajwani2, Nicholas Woodhouse3.   

Abstract

OBJECTIVES: Adrenocorticotropic hormone (ACTH) overproduction is usually due to a pituitary tumour which is often not visible on magnetic resonance imaging (MRI). However, ACTH overproduction may be due to an ectopic source. This study aimed to develop a simple non-invasive technique to differentiate these sources.
METHODS: This study took place in King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia, and Sultan Qaboos University Hospital, Muscat, Oman, between 1988 and 2012. Serum cortisol levels were measured in nine patients with ACTH-dependent Cushing's syndrome before and during a 72-hour trial of octreotide. All patients underwent computed tomography (CT) scans. MRI scans were performed on six patients.
RESULTS: CT scans were abnormal in three patients with ectopic ACTH production. MRI scans showed that three patients had pituitary microadenomas. Serum cortisol levels returned to normal in those with confirmed ectopic ACTH production. No response was found in the other six patients.
CONCLUSION: A 72-hour trial of octreotide is recommended for patients with ACTH-dependent Cushing's syndrome and a normal pituitary MRI. This trial will be a useful alternative to petrosal sinus sampling.

Entities:  

Keywords:  Adrenocorticotrophic Hormone; Cushing’s Syndrome; Investigational Therapies; Octreotide; Oman; Saudi Arabia; Somatostatin Receptors

Year:  2015        PMID: 25685371      PMCID: PMC4318592     

Source DB:  PubMed          Journal:  Sultan Qaboos Univ Med J        ISSN: 2075-051X


  11 in total

1.  Diagnosis and management of ACTH-dependent Cushing's syndrome: comparison of the features in ectopic and pituitary ACTH production.

Authors:  T A Howlett; P L Drury; L Perry; I Doniach; L H Rees; G M Besser
Journal:  Clin Endocrinol (Oxf)       Date:  1986-06       Impact factor: 3.478

2.  Cushing's Disease: Sustained remission in five cases induced by medical therapy with the dopamine agonist cabergoline.

Authors:  Omayma Elshafie; Anjum Osman; Fatima Aamer; Ali Al-Mamari; Njy Woodhouse
Journal:  Sultan Qaboos Univ Med J       Date:  2012-11-20

3.  Glucocorticoids down-regulate somatostatin receptors on pituitary cells in culture.

Authors:  A Schonbrunn
Journal:  Endocrinology       Date:  1982-04       Impact factor: 4.736

4.  Cushing's Disease: Pituitary Surgery versus Adrenalectomy.

Authors:  Omayma El-Shafie; Fatma B Abid; Nayal Al-Kindy; Dilip Sankhla; Nicholas J Woodhouse
Journal:  Sultan Qaboos Univ Med J       Date:  2008-07

5.  Adrenocorticotropic hormone-dependent Cushing's syndrome: sensitivity and specificity of inferior petrosal sinus sampling.

Authors:  F S Bonelli; J Huston; P C Carpenter; D Erickson; W F Young; F B Meyer
Journal:  AJNR Am J Neuroradiol       Date:  2000-04       Impact factor: 3.825

Review 6.  The Cushing syndrome: an update on diagnostic tests.

Authors:  T B Kaye; L Crapo
Journal:  Ann Intern Med       Date:  1990-03-15       Impact factor: 25.391

7.  Lung carcinoid with Cushing's syndrome: control of serum ACTH and cortisol levels using SMS 201-995 (sandostatin).

Authors:  P R Hearn; C L Reynolds; K Johansen; N J Woodhouse
Journal:  Clin Endocrinol (Oxf)       Date:  1988-02       Impact factor: 3.478

8.  Clinical significance of elevated serum chromogranin A levels.

Authors:  U Syversen; H Ramstad; K Gamme; G Qvigstad; S Falkmer; H L Waldum
Journal:  Scand J Gastroenterol       Date:  2004-10       Impact factor: 2.423

9.  Acute and long-term effects of octreotide in patients with ACTH-dependent Cushing's syndrome.

Authors:  N J Woodhouse; S Dagogo-Jack; M Ahmed; R Judzewitsch
Journal:  Am J Med       Date:  1993-09       Impact factor: 4.965

10.  Ectopic Cushing's syndrome caused by a pulmonary ACTH-secreting tumor in a patient treated with octreotide.

Authors:  Pedro Rodrigues; José Luís Castedo; Margarida Damasceno; Davide Carvalho
Journal:  Arq Bras Endocrinol Metabol       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.